Neuro-Orthopedic Registry of the University Hospital of Toulouse
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Midi-Pyrénées
-
Toulouse, Midi-Pyrénées, France, 31059
- CHU de Toulouse
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- ADULT
- OLDER_ADULT
- CHILD
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
Patient with a neurological condition that benefits:
- An injection of botulinum toxin in the context of spasticity : about 20 / week
- Pre or post-therapeutic clinical evaluation (botulinum toxin or surgery): approximately 10 / week
- Clinical or instrumental evaluation of the walking or upper limb (Physiological Functional Explorations): about 10 / week
- A medical and surgical multidisciplinary consultation about spasticity : about 15 / month
- A discussion during neuroorthopedic multidisciplinary consultation meeting about the patient's file and anomalies of walking: about 8 / month
- Implementation of a Baclofen pump (Neurosurgery): about 2 / month
- Functional surgery of the upper or lower limb (locomotor institute, orthopedic surgery and traumatology): about 4 / sem
Exclusion Criteria:
Patient (or the legal representative) who opposes the data collection.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Patients group
Patients follow-up in hospital will have data collection
|
data collection about symptoms without any specific clinical or biological intervention
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Neurologic symptoms
Time Frame: Each year until five years
|
Data collection
|
Each year until five years
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: David Gasq, University Hospital, Toulouse
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 14 7321 03
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neurologic Disorder
-
NCT07524790Not yet recruiting
-
NCT06866730Recruiting
-
NCT06382467Not yet recruitingNeurologic Disorder
-
NCT05940584Recruiting
-
NCT05652946Recruiting
-
NCT05173506Completed
-
NCT06111677Completed
-
NCT05506306Not yet recruiting
-
NCT04171973Completed
Clinical Trials on Data collection
-
NCT01890603CompletedHealth Information Technology | Nurse Based Care Management
-
NCT05025969Completed
-
NCT01502150Unknown
-
NCT01365390CompletedInfections, Streptococcal
-
NCT03237299Completed
-
NCT04323709CompletedCardiogenic Shock | Refractory Shock
-
NCT06443333RecruitingMultiple Sclerosis | Myasthenia Gravis | Autoimmune Encephalitis | Acute Disseminated Encephalomyelitis | NMO Spectrum Disorder | Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease
-
NCT06350656RecruitingCerebrospinal; Disorder
-
NCT02855879CompletedCoronary Artery Bypass Graft | Anomalies in Glucose Metabolism